Mesoblast Limited is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Melbourne, Victoria, AU. In its latest annual figures on file, for the fiscal year ended 2025-06-30, it reported revenue of $11 million and a loss of $102 million (its filed statements).
Pre-revenue companyBiological Products, (No Diagnostic Substances)Melbourne, Victoria, AUfilings since 20057 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2836), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.4 out of ten, 7 of 9 metrics filed and 2 estimated: past 4.2 out of ten, present 5.1 out of ten, future 6.4 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.0 out of ten. No warning events in its filings since 2017. 80th percentile among 159 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 2.8 out of ten. -9.6% a year over 10 filed years; profitable in 0 of 10. 28th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 3.7 out of ten. CrossAssetData estimate 3.7/10, confidence 35 of 100 (one part). 37th percentile among 146 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 5.2 out of ten. ROE -17%: lost 17¢ per shareholder dollar. Leverage 24%: owes 24¢ per asset dollar. 52nd percentile among 147 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 5.0 out of ten. bottom 50% of 102 in its family; net margin -593.9%. 50th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 130 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 4.0 out of ten. bottom 41% of 92 in its family for room to expand. 41st percentile among 92 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 8.1 out of ten. top 19% of 100 in its family for growth drivers. 81st percentile among 100 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 6.6 out of ten. top 34% of 72 in its family for expectations against reality. 66th percentile among 72 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-08-27 for the period ended 2026-06-30 (on EDGAR). Newest filing: Form 6-K, 2026-09-24. Filings on record since 2005. Read from EDGAR 2026-10-12.
Who runs it
Itescu, Silviu (CEO and Managing Director); Obrien, James Michael (Chief Financial Officer); Rose, Eric Allen (Chief Medical Officer,Director); Cobley, Lynette Elizabeth (director); George, Gregory (director); Burns, William Murray (director); Bell, Jane Catherine (director); Facchina, Philip James (director); Krause, Philip R. (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.